SK

Satya Kameswari Vakkalanka

Active Director Director DIN 01544061
DIN 01544061 First appointment Aug 2007 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 1 historical roles
Total affiliations 5 Since Aug 2007
Shareholding value •••• Premium profile

About Satya Kameswari Vakkalanka

Data last updated:

Satya Kameswari Vakkalanka is a Director at Fenix Research Labs Private Limited (since 2008), Director at Sirak Pharmaceuticals Private Limited (since 2008) and Designated Partner at Zaian Remedies Llp (since 2025), and holds 1 more current directorship. The companies operate in Pharma and Chemicals. The 2 current companies with reported revenue have a combined latest revenue of ₹14.58 Cr; the largest is Fenix Research Labs Private Limited at ₹11.62 Cr (FY 2025). Earlier, Satya Kameswari Vakkalanka was a Director at Zanthera Pharmaceuticals Private Limited (from 2007).

DIN 01544061
Primary Designation Director
Industry Pharma
First Appointment 08 Aug 2007
Oldest Company Age 19 yrs
Largest company Fenix Research Labs Private Limited · ₹11.62 Cr (FY 2025)
Combined revenue ₹14.58 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Fenix Research Labs Private Limited U24239TG2008PTC059967
Director30 Aug 20082008₹11.62 Cr (FY 2025)Active
Director08 Jan 20082008₹2.97 Cr (FY 2024)Active
Designated Partner21 Feb 20252025Active
Designated Partner29 Apr 20212021Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director08 Aug 20072007Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Sirak Research Labs Llp
Zanthera Pharmaceuticals Private Limited
Sirak Pharmaceuticals Private Limited
Fenix Research Labs Private Limited
Premium access

Shareholding and investment profile for Satya Kameswari Vakkalanka

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Satya Kameswari Vakkalanka

Satya Kameswari Vakkalanka currently holds 4 directorships: Fenix Research Labs Private Limited (Director, since 30 Aug 2008, revenue ₹11.62 Cr (FY 2025)); Sirak Pharmaceuticals Private Limited (Director, since 08 Jan 2008, revenue ₹2.97 Cr (FY 2024)); Zaian Remedies Llp (Designated Partner, since 21 Feb 2025); Sirak Research Labs Llp (Designated Partner, since 29 Apr 2021).

Satya Kameswari Vakkalanka was first appointed on 08 Aug 2007 as Director at Zanthera Pharmaceuticals Private Limited. The most recent appointment on record is 21 Feb 2025 at Zaian Remedies Llp.

The 2 current companies of Satya Kameswari Vakkalanka that report revenue have a combined latest revenue of ₹14.58 Cr: Fenix Research Labs Private Limited ₹11.62 Cr (FY 2025); Sirak Pharmaceuticals Private Limited ₹2.97 Cr (FY 2024).

Satya Kameswari Vakkalanka held 1 earlier board appointment: Zanthera Pharmaceuticals Private Limited (Director, from 08 Aug 2007).

The current boards of Satya Kameswari Vakkalanka's companies include Pranav Chirayu Amin (Fenix Research Labs Private Limited), Shaunak Chirayu Amin (Fenix Research Labs Private Limited), Thappali Ramaswamy Sethuraman Satheesh Manikandan (Fenix Research Labs Private Limited), Sita Samyukta Vakkalanka (Sirak Pharmaceuticals Private Limited), Swaroopkumar Venkata Satya Vakkalanka (Sirak Pharmaceuticals Private Limited), Abhay Vishwasrao Muthal (Zaian Remedies Llp), among others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available